Insight Molecular Diagnostics Inc. (IMDX) Stock Forecast & Price Target
Insight Molecular Diagnostics Inc. · NASDAQ
$4.25+0.13 (+3.03%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Insight Molecular Diagnostics Inc, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $8.00 to $12.00, a moderate spread. The average target of $9.67 sits 127% above the current $4.25. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 2 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.23 next quarter toward $-0.80 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Strong Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Insight Molecular Diagnostics Inc.
As of Sep, 3 of 3 firms rate IMDX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
IMDX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.23
Range $-0.24 – $-0.22 · 2 analysts
Next period, 2 analysts expect Insight Molecular Diagnostics Inc. to earn $-0.23 a share (range $-0.24 – $-0.22), versus — a year earlier. Full-year consensus is $-0.93, growing to $-0.80 the year after.
REVENUE · NEXT QUARTER
$473.7K
Range $100.0K – $1.1M · 2 analysts · -58% YoY
Revenue is expected to reach $473.7K (range $100.0K – $1.1M), -58.4% year-over-year. Full-year consensus is $960.0K, rising to $6.7M next year.
Top analysts covering Insight Molecular Diagnostics Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IMDX.
#1
Mike Matson
Needham · Rank #210
Buy
$9.00+111.5% to target
Overall win rate
34%
+ Follow
#2
TF
Thomas Flaten
Lake Street · Rank #238
Buy
$12.00+182.0% to target
Overall win rate
40%
+ Follow
#3
Mark Massaro
BTIG
Hold
No targeton IMDX
Coverage
—
+ Follow
IMDX stock forecast FAQ
What is IMDX's average 12-month price target?+
The 3 analysts with a live target average $9.67 for Insight Molecular Diagnostics Inc. over the next 12 months, ranging from a $12.00 high to a $8.00 low.
Is IMDX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for IMDX?+
The Street-high target is $12.00 (Lake Street), and the Street-low is $8.00 (LUCID CAPITAL MARKETS). The average of all 3 active targets is $9.67.
How many Wall Street analysts cover IMDX?+
3 analysts have an active rating on Insight Molecular Diagnostics Inc., and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering IMDX?+
Among analysts who currently cover IMDX, Mike Matson of Needham has the strongest overall Quantellect track record (Rank #210). Their current call is Buy with a $9.00 target.
What is Insight Molecular Diagnostics Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.23 per share (range $-0.24 – $-0.22) across 2 analysts. Full-year EPS is projected at $-0.93, rising to $-0.80 the following year.
How much revenue is Insight Molecular Diagnostics Inc. expected to report next quarter?+
Consensus revenue is $473.7K (range $100.0K – $1.1M). Full-year revenue is projected at $960.0K, growing to $6.7M next year.
Have analysts been upgrading or downgrading IMDX lately?+
As of Sep, 3 of 3 firms rate IMDX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IMDX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
LUCID CAPITAL MARKETS
